Lv1
40 积分 2025-07-25 加入
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
1个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
1个月前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
5个月前
已完结
Ocular toxicities of fibroblast growth factor receptor inhibitors: A review
6个月前
已完结
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
7个月前
已完结
The Skin Picking Impact Scale: Factor structure, validity and development of a short version
7个月前
已完结
DRUG-ASSOCIATED PRIMARY ACUTE PANCREATITIS
7个月前
已完结
Drug-induced acute pancreatitis: Prevalence, Causative agents, and Outcomes
7个月前
已完结
Recommendations for the Use of White Blood Cell Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
8个月前
已完结
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
11个月前
已完结
皖公网安备34019202002308
